EGFR and lung cancer: We first established EGFR TKI-resistant models through long-term treatments with gefitinib (GEF) or osimertinib (OSI) in human EGFR-mutant lung cancer cell line PC9 xenograft tumors (Fig. 1A and Fig. S1A and B, F–G).